Overview

Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma

Status:
Completed
Trial end date:
2018-10-14
Target enrollment:
Participant gender:
Summary
RATIONALE: Imaging procedures that use aminolevulinic acid (ALA) may help find and diagnose residual tumor in participants with grade IV malignant astrocytoma who are undergoing surgery to remove the tumor. PURPOSE: Our primary long-term goal is to improve the completeness of surgical resection of malignant brain tumor through image- guided fluorescence localization. We hypothesize that the use of qualitative fluorescence imaging and point PpIX concentration quantification will enable more complete tumor resection than normal direct (i.e., white light) visualization, and thereby improve participant survival.
Phase:
Phase 2
Details
Lead Sponsor:
Andrew Sloan, MD
Case Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Aminolevulinic Acid